IND application approved
On August 12, 2024, Yither biotech (Shanghai) Co., Ltd (Yither Bio) and its parent company Ab&B Bio-Tech Co., Ltd (hereinafter referred to as “Ab&B Bio”)
jointly applied for an IND application for a Class I new drug, "Recombinant Herpes zoster Vaccine (CHO Cells)", which was approved by the Drug Evaluation Center (CDE) of the China National Medical Products Administration.

Source: Government Service Website of the Drug Evaluation Center of the National Medical Products Administration

Regarding the recombinant herpes zoster vaccine (CHO cells)
Herpes zoster (HZ) is a kind of infectious diseases that mainly affects nerves and skin caused by reactivation of Varicella zoster virus (VZV). The main characteristic is clustered blisters distributed in a band shape,     accompanied by obvious neuropathic pain, which becomes more severe with age. This disease is common in elderly, immunocompromised, and immunocompromised patients, and has a certain recurrence rate. At present, there is no effective treatment for shingles, and vaccination is the preferred and effective means of preventing shingles.

The recombinant herpes zoster vaccine (CHO cells) approved this time utilizes the company's multiple independent intellectual property innovative technologies and officially authorized high expression cell matrix, especially the independently developed and screened innovative adjuvant system, which has obvious advantages and eliminates dependence on foreign adjuvant technology. Preclinical studies have shown that this product can induce the production of high levels of specific antibodies and CD4+T cell responses simultaneously, with high immunogenicity and safety. At the same time, the R&D team has optimized the production process to make it easier to scale up and achieve higher protein production, making subsequent commercial production more convenient and efficient.

More news
Recently, Ab&B Bio's drug production license change has been approved by the Jiangsu Provincial Drug Administration, adding the production scope of "influenza virus subunit vaccine", marking the company's successful acquisition of the production license for trivalent influenza virus subunit vaccine. This is an unremitting effort made by the company in response to the WHO's recommendation this year that influenza vaccines should no longer include B/Yamagata lineage components. The company acted quickly to meet market demand and achieve the early launch of trivalent influenza virus subunit vaccines, scientifically respond to influenza prevention and control, and provide multiple influenza vaccine options for society!